bone loss

PFI-4 is a potent and selective and cell-permeable BRPF1 bromodomain inhibitor.

BCI hydrochloride ((E)-BCI hydrochloride) is a selective dual-specificity phosphatase 6 (DUSP6) inhibitor that inhibits RANKL-mediated osteoclastogenesis and attenuates oophorectomy-induced bone loss.BCI hydrochloride has anti-inflammatory activity, reduces reactive oxygen species (ROS) production, and partially reverses AE-induced bone loss. BCI hydrochloride has anti-inflammatory activity and can reduce reactive oxygen species (ROS) production, partially reverse AE-induced cytotoxicity, and increase ERK activity, which can be used to study inflammatory diseases.

Droloxifene (3-Hydroxytamoxifen), a tamoxifen derivative, is an oral active and selective estrogen receptor modulator.Droloxifene induced p53 expression and apoptosis in McF-7 cells.Fluroxifene has anti-estrogen and anti-implantation effects.Fluroxifene prevented bone loss in ovariectomized rats.

Royal Jelly Acid (Queen Bee Acid) is a major fatty acid found in royal jelly that promotes neuronal growth and protection and reduces anxiety. Royal Jelly Acid induces reactive oxygen species (ROS)-mediated apoptosis in A549 cells, improves non-alcoholic fatty liver disease by activating the AMPK-α signaling pathway, and reduces bone loss by inhibiting the NF-κB signaling pathway downstream of FFAR4. Royal Jelly Acid also exhibits inhibitory effects against various bacteria and fungi, including Aspergillus niger, mold, and Staphylococcus aureus. By targeting aspartyl β-hydroxylase and inhibiting chondrocyte senescence, Royal Jelly Acid exerts a preventive and therapeutic effect against osteoarthritis.

Astramembrangenin (Cycloastragenol (Astramembrangenin)) is a triterpenoid saponin compound and a hydrolysis product of the main active ingredient in Astragalus membranaceus. Cycloastragenol (CAG) may have a novel therapeutic role in depression

6-Raloxifene-β-D-glucopyranoside is a benzothiophene glucuronidated at the 6' position. It is a selective and orally active estrogen receptor antagonist. 6-Raloxifene-β-D-glucopyranoside can be used for inhibiting bone loss, resorption, and lowering lipid

Otenaproxesul (ATB 346) is a novel hydrogen sulphide-releasing derivative of naproxen with markedly reduced toxicity.

CXM102 is an activator of autophagy. This compound induces autophagy in aged BMSCs, rejuvenating them and promoting their preferential differentiation into osteoblasts. CXM102 enhances the nuclear translocation of transcription factor EB (TFEB) and the formation of osteoblasts. In middle-aged male mice, it stimulates bone anabolic metabolism, reduces marrow adipocytes, delays bone loss, lowers serum inflammation levels, reduces organ fibrosis, and extends lifespan.

E0924G is an orally active PPARδ agonist with an EC50 of 2.82 μM. It enhances the upregulation of osteoprotegerin (OPG) expression, with an EC50 of 0.29 μM. E0924G reduces RANKL-induced osteoclast differentiation and inhibits F-actin ring formation in RAW264.7 macrophages. Additionally, E0924G modulates bone density and bone loss in models of ovariectomy (OVX) and age-related osteoporosis.

Raloxifene (LY139481) is a selective estrogen receptor modulator that exhibits both estrogen agonist and antagonist activities at certain sites, with antiviral activity against viruses like Ebola, influenza, and HCV, useful for studying viral infections.

SPA0355 is a thiourea derivative with antioxidant and anti-inflammatory properties. It inhibits RANKL (receptor activator of nuclear factor κB ligand)-induced osteoclastogenesis in primary bone marrow-derived macrophages and suppresses the activation of MAPKs, Akt, and NF-κB pathways. Furthermore, SPA0355 enhances osteoblast differentiation by increasing alkaline phosphatase activity and mineralized nodule formation. It protects ovariectomized mice from bone loss by stimulating osteoblast differentiation and inhibiting osteoclast resorption, making it a potential candidate for studying postmenopausal osteoporosis.

BT-Amide is an orally active Pyk2 kinase (Pyk2kinase) inhibitor with an IC50 of 44.69 nM. It prevents glucocorticoid-induced bone loss and demonstrates bone-protective activity in C57BL/6 mice.

Anti-osteoporosis agent-8 (Compound 4aa) is a RANKL inhibitor, capable of preventing RANKL-induced osteoclastogenesis and osteoclast differentiation, with an IC50 of 2.41 μM. Furthermore, Anti-osteoporosis agent-8 has been shown to mitigate bone loss in an ovariectomized (OVX) mouse model.

GL64 is a selective agonist of ADGRD1 with an EC50 of 3.98 μM. It shows low selectivity for the subtypes ADGRD2, ADGRG5, ADGRG6, CELSR1, CELSR2, CELSR3, and ADGRG4. GL64 activates ADGRD1 by mimicking the satchel sequence. It regulates osteoclast maturation through the cAMP-PKA-NFATC1 pathway. Both in vivo and in vitro, GL64 effectively inhibits osteoclastogenesis and prevents bone loss. This compound is suitable for research into osteoclast-related diseases.

AS2795440 is a PIKfyve inhibitor. It selectively suppresses the production of pro-inflammatory cytokines such as IL-12p40 and IL-6 and the activation of B cells, without affecting Ca2+ signaling. In a mouse model of adjuvant-induced arthritis (AIA), AS2795440 significantly reduces joint inflammation and bone loss. This compound is useful for researching inflammatory and autoimmune diseases like rheumatoid arthritis, psoriasis, and inflammatory bowel disease.

Anti-osteoporosis agent-12 (Compound 18) is an orally active pyrazole-fused betulinic acid derivative that exhibits strong anti-osteoporotic properties. It powerfully inhibits RANKL-induced osteoclastogenesis in RAW264.7 cells, with an IC50 of 7.96 nM. Additionally, Anti-osteoporosis agent-12 dose-dependently improves key micro-CT parameters of bone, reduces serum bone resorption marker levels (CTx), and effectively prevents bone loss induced by ovariectomy. This agent is useful for osteoporosis research.

SH543 is a potent anti-osteoporosis agent that inhibits RANKL-induced osteoclastogenesis, with an IC50 value of 3.3 nM. It directly binds to KEAP1, activating the Nrf2-HO-1 antioxidant pathway, reducing reactive oxygen species (ROS) levels, and inhibiting PI3K-AKT and MAPK signaling pathways. SH543 alleviates pathological bone loss in ovariectomized mice and is useful for osteoporosis research.

E8431 is a DCSTAMP antagonist, where DCSTAMP is a crucial fusion protein that coordinates cell-cell fusion during osteoclastogenesis. E8431 inhibits cytoskeletal reorganization mediated by the RAP1B-RAC1 signaling pathway. It has the ability to prevent pre-osteoclast fusion, suppress bone resorption, and stimulate PDGFBB secretion, thereby promoting bone and vessel formation. E8431 effectively reduces bone loss in mouse models induced by ovariectomy. This compound can be used for osteoporosis research.

L-006235 is a potent and reversible inhibitor of cathepsin K with IC50 of 0.25 nM.

Thonzonium bromide is a mono-cationic surfactant that is structurally similar to Farnesol as an antimicrobial agent. It inhibits proton transport in a dose-dependent manner (EC50=69 μM). It inhibits RANKL-induced osteoclast formation and bone resorption in vitro and prevents LPS-induced bone loss in vivo.

GSK 650394 is an inhibitor of serum- and glucocorticoid-regulated kinases (SGK) that inhibits SGK1 and SGK2 (IC50=62/103 nM). GSK 650394 has antitumor activity and also inhibits osteoclast differentiation and prevents bone loss.

ABD-295 is an antiresorptive agent, osteoclast inhibitor, and biphenylsulfide derivative. ABD-295 has potent inhibitory effects on osteoclastic bone resorption in vitro. ABD-295 prevents ovariectomy-induced bone loss in vivo.

M-5011 is a non-steroidal anti-inflammatory drug and immunomodulator potentially for the treatment of inflammation and pain. M-5011 had an effective antinociceptive activity (ED50 value) of 0.63 mg/kg. M-5011 partially inhibits the generalized bone loss a

CGP77675 hydrate is an orally active, potent inhibitor of Src family kinases. It inhibits the phosphorylation of peptide substrates and autophosphorylation of purified Src (IC50: 5-20 and 40 nM, respectively), as well as Src, EGFR, KDR, v-Abl, and Lck with IC50s of 0.02, 0.15, 1.0, 0.31, and 0.29 μM, respectively. CGP77675 hydrate may be useful for treating diseases associated with elevated bone loss and has anticancer activity [1].